A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2018
Price : $35 *
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 21 Dec 2016 Status changed from active, no longer recruiting to completed.
- 25 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 19 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.